Astellas Bullish on Zolbetuximab's Prospects in Gastric Cancer After Two Positive Phase III Readouts
Premium
The firm will submit data from the GLOW and SPOTLIGHT studies to regulators and seek approval for zolbetuximab plus chemo in CLDN18.2-positive HER2-negative advanced gastric cancer.
Black Women With High Cancer Risk Lack Access to Genetics Experts, Specialists, OSU Study Finds
Premium
After interviews showed Black women are more likely to seek cancer risk information from PCPs, Ohio State researchers are delving deeper into disparities research.
Artera Raises $90M to Market Test for Assessing Prostate Cancer Progression, Treatment Benefit
Premium
The San Francisco-based company will use the funds to commercialize the ArteraAI Prostate Cancer test in the US and internationally, and develop similar tests for other cancers.
White House Report Outlines Goals to Advance Genomic Research, Precision Therapy Development
The report, on goals for biotechnology and biomanufacturing in the US, suggests areas of investment including multiomics, cell therapies, gene editing, and microbial genome sequencing.
Thermo Fisher Scientific's IonTorrent Genexus platform can provide cancer panel results in about a day, but data on clinical impact of the fast turnaround has not yet been produced.
Bayer to Assess Nubeqa in High-Risk, Early-Stage Hormone-Sensitive Prostate Cancer
The firm will enroll patients to the Phase III clinical trial if they have a positive PSMA PET scan and their PSA score doubles within a year.
Flare Therapeutics Raises $123M in Oversubscribed Series B Funding Round
The firm will use the proceeds to start a clinical trial this year for its lead precision oncology candidate, a PPARG inhibitor, in urothelial cancer.